Reports Q4 revenue $21.28M, consensus $20.58M. “It was another phenomenal quarter for Eton with meaningful contributions from key products across our portfolio including INCRELEX, ALKINDI SPRINKLE, KHINDIVI, and GALZIN. The strong fourth quarter helped us cap off a transformational 2025. During the year we launched three major products, INCRELEX, GALZIN, and KHINDIVI, and delivered $80 million in total revenue, more than doubling our 2024 revenue,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals (ETON).
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETON:
- Is ETON a Buy, Before Earnings?
- Eton Pharmaceuticals participates in a conference call with Craig-Hallum
- Eton Pharmaceuticals price target raised to $30 from $29 at Craig-Hallum
- Eton Pharmaceuticals Acquires U.S. Rights to HEMANGEOL
- Eton in-licenses U.S. commercialization rights to HEMANGEOL from Pierre Fabre